Teva Pharmaceuticals
U.S. Headquarters
1090 Horsham Road
North Wales
Pennsylvania
19454
United States
Tel: 888-838-2872
Website: https://www.tevausa.com/
About Teva Pharmaceuticals
Teva Pharmaceutical Industries Ltd. develops, produces and markets ethical drugs, generic drugs, and fine chemicals for the pharmaceutical industry and disposable products for hospitals and home care services.
YEAR FOUNDED:
1901
CLINICAL TRIAL:
Please click here for clinical trial information.
PRODUCTS:
All Products
1677 articles with Teva Pharmaceuticals
-
Teva Announces New Findings Highlighting Potential of ProAir® Digihaler® (albuterol sulfate) Inhalation Powder to Address Asthma Treatment Challenges
5/17/2022
Teva Announces New Findings Highlighting Potential of ProAir ® Digihaler ® (albuterol sulfate) Inhalation Powder to Address Asthma Treatment Challenges.
-
Ontario, British Columbia, Nova Scotia, New Brunswick, and Newfoundland, Join a Growing List of Provinces Providing Public Drug Plan Reimbursement for Teva Canada’s AJOVY® (fremanezumab), for the Preventive Treatment of Migraine in Adults
5/17/2022
Teva Canada Limited, a subsidiary of Teva Pharmaceutical Industries Ltd., welcomes the recently announced public formulary coverage for AJOVY® (fremanezumab) by Ontario, British Columbia, Nova Scotia, New Brunswick, and Newfoundland.
-
United Kingdom first to grant licence for Teva’s ophthalmology biosimilar Ongavia (ranibizumab)▼
5/17/2022
Teva Pharmaceutical Industries Ltd welcomes the UK Medicines & Healthcare Regulatory Agency decision to grant a licence for Ongavia®, a biosimilar to Lucentis®, an eye injection.
-
Teva to Present Latest Research From Neurology Portfolio at the 2022 American Psychiatric Association Annual Meeting
5/17/2022
Teva Pharmaceuticals, a U.S. affiliate of Teva Pharmaceutical Industries Ltd. (NYSE and TASE: TEVA), today announced four data presentations for AUSTEDO® (deutetrabenazine) tablets and TV-46000/mdc-IRM.
-
Teva to Present Findings on Short-Acting Beta Agonist (SABA) Use in Asthma Patients and the Potential of ProAir® Digihaler® (albuterol sulfate) Inhalation Powder
5/12/2022
Teva to Present Findings on Short-Acting Beta Agonist (SABA) Use in Asthma Patients and the Potential of ProAir ® Digihaler ® (albuterol sulfate) Inhalation Powder to Help Inform Treatment Decisions at American Thoracic Society 2022 Annual Meeting.
-
AbbVie and Teva are reportedly ready to pay over $5 billion to quiet the over 3,500 opioid liability lawsuits filed against them over their painkillers.
-
Life Science industries are seeing massive financial fluctuations in how they're handling the COVID-19 pandemic, but there is some optimism of a recovery by biopharma executives.
-
Teva announced that it had reached a deal with Lupin over Lupin’s Abbreviated New Drug Application (ANDA) for generic deutetrabenazine - an upcoming competitor to Hungtington's drug Austedo.
-
The FDA has issued a Complete Response Letter (CRL) for TV-46000/mdc-IRM (risperidone extended-release injectable suspension for subcutaneous use) to Teva Pharmaceuticals and MedinCell.
-
Teva and MedinCell Receive Complete Response Letter for TV-46000/mdc-IRM
4/19/2022
Teva Pharmaceuticals, a U.S. affiliate of Teva Pharmaceutical Industries Ltd., and MedinCell announced that the U.S. Food and Drug Administration has issued a Complete Response Letter regarding the New Drug Application for TV-46000/mdc-IRM for the treatment of schizophrenia.
-
Teva to Host Conference Call to Discuss First Quarter 2022 Financial Results at 8 a.m. ET on May 3, 2022
4/4/2022
Teva Pharmaceutical Industries Ltd. (NYSE and TASE: TEVA) announced today that it will issue a press release on its first quarter 2022 financial results on Tuesday, May 3, 2022 at 7:00 a.m. ET.
-
Teva to Present New Analyses of AJOVY® (fremanezumab-vfrm) Injection and AUSTEDO® (deutetrabenazine) Tablets at 2022 American Academy of Neurology Annual Meeting
4/1/2022
Teva to Present New Analyses of AJOVY ® (fremanezumab-vfrm) Injection and AUSTEDO ® (deutetrabenazine) Tablets at 2022 American Academy of Neurology Annual Meeting.
-
Teva Pharmaceuticals and AbbVie will pay the state of Rhode Island a combined $28.5 million to settle opioid-related claims against the companies.
-
Bristol Myers Squibb’s moneymaker cancer drug Revlimid has finally found a competitor in Israel-based Teva Pharmaceuticals’ generic version, lenalidomide.
-
Teva Announces Launch of a First Generic Version of Revlimid® (lenalidomide capsules), in the U.S.
3/7/2022
Teva Pharmaceuticals, a U.S. affiliate of Teva Pharmaceutical Industries Ltd. (NYSE and TASE: TEVA), announced today the launch of a first generic version of Revlimid®1 (lenalidomide capsules), in 5mg, 10mg, 15mg, and 25mg strengths, in the United States.
-
Teva Pharmaceuticals reported solid earnings for the full year of 2021, posting $15.9 billion in revenues alongside gains of $4.1 billion from the fourth quarter alone.
-
Teva Reports Fourth Quarter and Full Year 2021 Financial Results
2/9/2022
Teva Pharmaceutical Industries Ltd. (NYSE and TASE: TEVA) today reported results for the year and the quarter ended December 31, 2021.
-
Teva to Host Conference Call to Discuss Fourth Quarter and Full Year 2021 Financial Results and 2022 Financial Guidance at 8 a.m. ET on February 9, 2022
1/18/2022
Teva Pharmaceutical Industries Ltd. (NYSE and TASE: TEVA) announced today that it will issue a press release on its fourth quarter and full year 2021 financial results, as well as on its financial guidance for 2022, on Wednesday, February 9, 2022 at 7:00 a.m. ET.
-
Teva to Present at the 40th Annual J.P. Morgan Healthcare Conference
1/4/2022
Teva Pharmaceutical Industries Ltd. (NYSE and TASE: TEVA) today announced that President & CEO Kåre Schultz will present at the virtual 40th Annual J.P. Morgan Healthcare Conference on Tuesday, January 11, 2022.
-
Teva Statement Following New York Jury Ruling in Opioids Trial
12/30/2021
Teva Pharmaceuticals, a U.S. affiliate of Teva Pharmaceutical Industries, Ltd. (NYSE and TASE: TEVA) strongly disagrees with today’s outcome and will prepare for a swift appeal as well as continue to pursue a mistrial.